2025 Europe Anti-Tuberculosis Drug Market Revenue Opportunities Report
Description
The 2025 Europe Anti-Tuberculosis Drug Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Tuberculosis Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Anti-Tuberculosis (TB) drug market in Europe are Johnson & Johnson, Otsuka Pharmaceutical, Pfizer, and Sanofi. Johnson & Johnson, through its Janssen division, is notable for developing innovative TB drugs like bedaquiline, particularly addressing drug-resistant TB strains. Otsuka Pharmaceutical, with its European subsidiary Otsuka Novel Products GmbH, holds marketing authorization for Deltyba® in Europe and is deeply engaged in expanding access to multidrug-resistant TB treatments while collaborating with European stakeholders. Pfizer and Sanofi also maintain significant European market presence, deploying extensive pharmaceutical expertise in anti-TB therapeutics and contributing to global TB control efforts.
Additionally, Novartis and Lupin Limited, while major global players, have a more pronounced focus outside Europe but are involved indirectly through partnerships and drug accessibility programs. Collaborative initiatives like the ERA4TB consortium, supported by European institutions and involving companies such as GlaxoSmithKline (GSK), complement these industry leaders by accelerating TB drug development within Europe. These companies’ engagement aligns with strategic public health goals driven by European research funds and multilateral efforts to combat tuberculosis, particularly drug-resistant forms, in the continent.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Tuberculosis Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Anti-Tuberculosis (TB) drug market in Europe are Johnson & Johnson, Otsuka Pharmaceutical, Pfizer, and Sanofi. Johnson & Johnson, through its Janssen division, is notable for developing innovative TB drugs like bedaquiline, particularly addressing drug-resistant TB strains. Otsuka Pharmaceutical, with its European subsidiary Otsuka Novel Products GmbH, holds marketing authorization for Deltyba® in Europe and is deeply engaged in expanding access to multidrug-resistant TB treatments while collaborating with European stakeholders. Pfizer and Sanofi also maintain significant European market presence, deploying extensive pharmaceutical expertise in anti-TB therapeutics and contributing to global TB control efforts.
Additionally, Novartis and Lupin Limited, while major global players, have a more pronounced focus outside Europe but are involved indirectly through partnerships and drug accessibility programs. Collaborative initiatives like the ERA4TB consortium, supported by European institutions and involving companies such as GlaxoSmithKline (GSK), complement these industry leaders by accelerating TB drug development within Europe. These companies’ engagement aligns with strategic public health goals driven by European research funds and multilateral efforts to combat tuberculosis, particularly drug-resistant forms, in the continent.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
